Evidence-Based GI
ACG EBGI: This Evidence-based summary looks at D’Haens G, Panaccione R, Baert F, et al. Risankizumab as Induction Therapy for Crohn’s Disease: Results from the Phase 3 ADVANCE and MOTIVATE Induction Trials. Lancet 2022;399(10340):2015-30.
ACG EBGI: Evidence-based summary reviews Ferrante M, Panaccione R, Baert F, et al. Risankizumab as maintenance therapy for moderately to severely active Crohn’s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal Phase 3 FORTIFY maintenance trial. Lancet 2022;399(10340):2031-2046.
Evidence-based summary reviews Yadlapati R, Gyawali CP, Masihi M, et al. Optimal Wireless Reflux Monitoring Metrics to Predict Discontinuation of Proton Pump Inhibitor Therapy. Am J Gastroenterol. 2022 Oct 1;117(10):1573-1582. doi.org/10.14309/ajg.0000000000001871.
This summary reviews Wong F, Pappas SC, Curry MP, et al. Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome. N Engl J Med. 2021 Mar 4;384(9):818-828.
Ozanimod for Moderate-Severe Ulcerative Colitis: Rethinking the Top-Down Treatment Algorithm Oriana Damas, MD1 and Philip Schoenfeld, MD, MSEd, MSc (Epi)2…
Continuing Anti-TNF Agents Past 24 Weeks of Pregnancy Associated with Fewer IBD Relapses with No Increase in Adverse Fetal Outcomes…
Donor Stool Product for FMT Decreases Recurrent Clostridioides difficile Infection: RBX2660 Is the First FDA-Approved Live Biotherapeutic Product Colleen R.…
NSAID Use and the Risk of IBD Exacerbations: Fact or Fiction? Philip N. Okafor, MD, MPH1 1Senior Associate Consultant, Department…
Evidence-Based GI: One Year Review Philip Schoenfeld, MD, MSEd, MSc (Epi) Chief (Emeritus), Gastroenterology Section, John D. Dingell VA Medical…
Vonoprazan, a Potassium-Competitive Acid Blocker, Is Superior to Lansoprazole for Managing Erosive Esophagitis Philip Schoenfeld, MD, MSEd, MSc (Epi) Chief…